Publication

Galectin-3 in heart failure: From biomarker to target for therapy

van der Velde, A. R., 2017, [Groningen]: Rijksuniversiteit Groningen. 295 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 1021 KB, PDF document

  • Chapter 1

    Final publisher's version, 1 MB, PDF document

  • Chapter 2

    Final publisher's version, 1 MB, PDF document

  • Chapter 3

    Final publisher's version, 1 MB, PDF document

  • Chapter 4

    Final publisher's version, 2 MB, PDF document

  • Chapter 5

    Final publisher's version, 1 MB, PDF document

  • Chapter 6

    Final publisher's version, 1 MB, PDF document

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

  • Chapter 8

    Final publisher's version, 1 MB, PDF document

  • Chapter 9

    Final publisher's version, 3 MB, PDF document

  • Chapter 10

    Final publisher's version, 6 MB, PDF document

  • Chapter 11

    Final publisher's version, 1 MB, PDF document

  • Appendices

    Final publisher's version, 1 MB, PDF document

  • Complete thesis

    Final publisher's version, 13 MB, PDF document

  • Propositions

    Final publisher's version, 79 KB, PDF document

  • Allart Rogier van der Velde
This thesis describes the role of galectin-3 in heart failure. Galectin-3 is a protein that is secreted in our body during inflammation and tissue damage. It becomes released into the blood stream and can be measured with a blood test. As a biomarker, galectin-3 can be used for risk stratification in patients with heart failure. In our studies, we show that repeated measurements provide incremental prognostic information. Furthermore, galectin-3 is a marker of subclinical disease: it can be used to identify subjects in the general population that will develop heart failure in the future. Galectin-3 is also involved in cardiac fibrosis and is released after myocardial infarction. Baseline galectin-3 measurements in patients with a myocardial infarction predict infarct size and cardiac function.
Another goal of this thesis was to further unravel galectin-3 biology. We show that galectin-3 levels increase upon severe hypertension or micro-albuminuria. In addition, renal function is an important determinant of the present galectin-3 level. Furthermore, blood group also determines galectin-3 level. Possibly, the biological activity of galectin-3 is regulated by glycosylation, the addition of sugar groups.
However, the most important feature of galectin-3 is to serve as a target for therapy. Pectins, which are complex sugars extracted from natural food sources, are able to inhibit galectin-3-mediated effects. Administration of pectins in an animal model attenuates cardiac fibrosis and preserves cardiac function. The concept of galectin-3 inhibition could be an interesting addition to the current heart failure treatment regimen.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date11-Jan-2017
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-6169-998-5
Electronic ISBNs978-90-77595-41-1
Publication statusPublished - 2017
Related Datasets
  1. Lifelines Biobank

    Bakker, S. (Creator), Dotinga, A. (Creator), Vonk, J. (Creator), Smidt, N. (Creator), Scholtens, S. (Creator), Swertz, M. (Creator), Wijmenga, C. (Creator), Wolffenbuttel, B. (Creator), Stolk, R. (Creator), Zon, van, S. (Creator), Rosmalen, J. (Creator), Postma, D. S. (Creator), Boer, de, R. (Creator), Navis, G. (Creator), Slaets, J. (Creator), Ormel, H. (Creator), Dijk, van, F. (Creator), Lifelines, 2006

    Dataset

View all (1) »

Download statistics

No data available

ID: 38571022